The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Dasatinib is approved by the U.S. Food and Drug Administration (FDA) as a second-generation ABL-class tyrosine kinase inhibitor for the treatment of newly diagnosed adult patients with Philadelphia (Ph)-positive acute lymphoblastic leukemia (ALL). The phase II Children’s Oncology Group (COG) AALL0622 (NCT00720109) trial showed promising efficacy and safety of dasatinib in combination with the AALL0031 (NCT00022737)-based intensive chemotherapy backbone in a small cohort of pediatric patients with Ph+ ALL.
Here, we summarize the results of the open-label, single-arm, phase II study, CA180-372/COG AALL1122 (NCT01460160) , recently published by Hunger et al.1 investigating the efficacy of dasatinib in combination with intensive chemotherapy in newly diagnosed pediatric patients with Ph+ ALL.
The CA180-372/COG AALL1122 study was a joint COG and European intergroup trial of post-induction treatment of Ph+ ALL (EsPhALL). Patients aged < 18 years with newly diagnosed Ph+ ALL and performance status of at least 60% received EsPhALL-based intensive chemotherapy plus dasatinib 60 mg/m² orally once daily from Day 15 of induction.
Minimal residual disease (MRD) was measured at three time points during therapy: at the end of induction 1A (the first four weeks of treatment), at the end of induction 1B (the second 4 weeks of treatment), and at the end of consolidation block three. Patients with MRD ≥ 0.05% after induction 1B or who remained MRD positive after receiving three consolidation blocks were classified as high risk and allocated to receive hematopoietic stem-cell transplantation in the first complete remission. The remaining patients were considered standard risk and received chemotherapy plus dasatinib for 2 years.
Overall, 109 patients were included in the trial and 106 received dasatinib (three patients were excluded). Patient characteristics are shown in Table 1.
Table 1. Patient characteristics*
CNS, central nervous system; HSCT, hematopoietic stem-cell transplantation. *Adapted from Hunger et al.1 |
|
Characteristic, % (unless otherwise stated) |
All treated patients (n = 106) |
---|---|
Median age at diagnosis, years |
9.4 |
Male |
54 |
Female |
46 |
CNS status |
|
CNS1 (no blasts) |
71 |
CNS2 (< 5 blasts per µL) |
24 |
CNS3 (≥ 5 blasts per µL) |
5 |
Not available |
1 |
Complete remission status |
|
Yes |
100 |
Risk status |
|
Standard risk |
82 |
High risk |
18 |
Treatment received |
|
Dasatinib and chemotherapy alone |
86 |
HSCT in first complete remission |
14 |
The trial met its primary efficacy endpoint.
Figure 1. The 3-year EFS in patients receiving dasatinib plus intensive chemotherapy vs AIEOP-BFM 2000
EFS, event-free survival.
Figure 2. The 3-year EFS patients receiving dasatinib plus intensive chemotherapy vs EsPhALL 2010
EFS, event-free survival; EsPhALL, European intergroup trial of post-induction treatment of Ph+ ALL.
Table 2. The most frequent adverse events*
NR, not reported. |
|||||||||||||
Any cause† |
Related to dasatinib |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Grade 1–2 |
Grade 3 |
Grade 4 |
Grade 5 |
Grade 1–2 |
Grade 3 |
Grade 4 |
|||||||
Infections |
|||||||||||||
Febrile neutropenia |
1 |
78 |
10 |
0 |
1 |
21 |
2 |
||||||
Bacteremia |
2 |
18 |
2 |
0 |
NR |
NR |
NR |
||||||
Sepsis |
0 |
9 |
25 |
1 |
0 |
3 |
3 |
||||||
Based on MRD analysis at the end of induction 1A, all 106 patients reached full remission. Immunoglobulin and T-cell receptor testing revealed that 35% of 86 patients were MRD-negative at the end of induction 1A; this number increased to 62% of 90 patients at the end of induction 1B, and to 89% of 85 patients at the end of consolidation block 3.
Dasatinib plus intensive chemotherapy showed promising efficacy with a manageable safety profile in newly diagnosed pediatric patients with Ph+ ALL. The 3-year EFS was similar to that of previous trials in patients with Ph+ ALL. To further improve the outcomes in children with Ph+ ALL, newer tyrosine kinase inhibitors represent potential strategies that could be investigated in the future trials.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content